Alonet

Alonet

atenolol

Manufacturer:

Y.S.P. Industries

Distributor:

Yung Shin
Concise Prescribing Info
Contents
Atenolol
Indications/Uses
Dosage/Direction for Use
Adult HTN 50-100 mg once daily. Angina pectoris 100 mg once daily or 50 mg bd. Elderly Dose may be reduced. Renal impairment, CrCl 15-35 mL/min/1.73 m2 50 mg daily, CrCl <15 mL/min/1.73 m2 50 mg on alternate days.
Administration
May be taken with or without food.
Contraindications
Hypersensitivity. Cardiogenic shock, uncontrolled heart failure, sick sinus syndrome, 2nd or 3rd degree heart block, untreated phaeochromocytoma, metabolic acidosis, bradycardia (<45 bpm), hypotension, severe peripheral arterial circulatory disturbances.
Special Precautions
Risk of hypersensitivity reaction including angioedema & urticaria. W/draw dose gradually over a period of 7-14 days. Monitor patients during withdrawal, especially those w/ ischaemic heart disease. Caution in patients w/ poor cardiac reserve; 1st degree heart block. Risk of increased number & duration of angina attacks in patients w/ Prinzmetal's angina. May mask symptoms of hypoglycaemia, particularly tachycardia, or signs of thyrotoxicosis. May cause a more severe reaction to a variety of allergens when given to patients w/ history of anaphylactic reaction to such allergens; risk of altered response to the usual doses of adrenaline used to treat allergic reactions. Avoid use in patients w/ reversible obstructive airways disease, unless clinically necessary. Risk of increase in airway resistance in asthmatic patients. Patients w/ severe renal impairment. Pregnancy & lactation.
Adverse Reactions
Bradycardia, cold extremities, postural hypotension, dizziness, fatigue, skin rash, dry eyes.
Drug Interactions
Additive effect on -ve inotropic effects w/ Ca channel blockers eg, verapamil & diltiazem, particularly in patients w/ impaired ventricular function &/or SA or AV conduction abnormalities. Increased risk of hypotension & cardiac failure w/ dihydropyridines (eg, nifedipine) in patients w/ latent cardiac insufficiency. Increased AV conduction time w/ digitalis glycosides. β-blockers may exacerbate the rebound HTN which can follow the withdrawal of clonidine. Potentiated effect on atrial conduction time & induction of -ve inotropic effect w/ class I anti-arrhythmics (eg, disopyramide) & amiodarone. Sympathomimetics (eg, epinephrine) may counteract the effect of β-blockers. Intensified blood sugar lowering effect of insulin & oral antidiabetic drugs. Decreased hypotensive effects w/ prostaglandin synthetase-inhibiting drugs eg, ibuprofen & indomethacin.
MIMS Class
Beta-Blockers
ATC Classification
C07AB03 - atenolol ; Belongs to the class of selective beta-blocking agents. Used in the treatment of cardiovascular diseases.
Presentation/Packing
Form
Alonet tab 100 mg
Packing/Price
10 × 10's
Form
Alonet tab 50 mg
Packing/Price
10 × 10's
Exclusive offer for doctors
Register for a MIMS account and receive free medical publications worth $768 a year.
Already a member? Sign in